Thanks to a licensing agreement with IASON GmbH, an Austrian-based company specialized in the production of nuclear medicine radiopharmaceuticals, AAA is now allowed to produce and sell IASOFLU in France. IASOFLU is a new 18F sodium fluoride pharmaceutical used to detect and stage skeletal metastasis, a highly common disease in patients suffering from breast and prostate cancer. IASOFLU is produced at the French site in Troyes and is benefiting from the support of the site’s R&D and production teams. The first doses have been delivered to Creil and Tenon hospitals.